Suppression of Epigenetic Brain Proteins Induces Autism-Like Syndrome
Regulation of a family of brain proteins known as bromodomain and extra-terminal domain containing transcription regulators (BETs) plays a key role in normal cognition and behavior, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published advanced online on September 21 and in print October 19 in The Journal of Experimental Medicine.
The Mount Sinai study focuses on epigenetics, the study of changes in the action of human genes caused by molecules that regulate when, where and to what degree our genetic material is activated, rather than focusing on genetic changes in the DNA code we inherit from our parents.
While scientists have traditionally focused on finding individual genes responsible for Autism Spectrum Disorders (ASD), recent research has found links between epigenetic regulation and ASD in human patients. Such regulation derives, in part, from the function of specialized protein complexes that bind to specific DNA sequences and either encourage or shut down the expression of a given gene.
Mount Sinai researchers found that BETs, a family of epigenetic regulators that bind to many different genes and contribute to the copying of these genes into messenger RNA, the template used by the cell to make proteins, play a key role in the regulation of normal neuronal development and function. The Mount Sinai study was conducted using a new type of pharmacological compound that does not inactivate BET proteins but, rather, prevents them from binding to the genes.
The research team developed a novel, highly specific, brain-permeable inhibitor of BET proteins called I-BET858. The compound was initially tested on in vitro cultured mouse neurons. The researchers found that it affected the function of a particular group of genes with known links to neuron development and synaptic functions. Importantly a significant number of the affected genes have been linked to ASD in humans. Subsequently, the study team evaluated the effect of I-BET858 when injected into mice. They found the compound was able to trigger selective changes in neuronal gene expression in the brain followed by development of an ASD-like syndrome.
“We found that chronic daily administration of I-BET858 in young mice led to the development of behavioral abnormalities consistent with an autism-like syndrome, including reduced sociability and preference for social novelty ” says Anne Schaefer, MD, PhD, Assistant Professor in the Department of Neuroscience and Psychiatry at the Friedman Brain Institute at the Icahn School of Medicine at Mount Sinai, who led the study.
“One of the most important outcomes of our study is that we found a link between I-BET858-induced ASD and the altered function of a rather limited group of genes,” says Dr. Schaefer. “Furthermore, our findings reinforce the idea that ASD could be caused not only by genetic alteration, but by environmental factors that reduce the efficiency of gene transcription into full length RNA during brain development. “
These studies also suggest that pharmacological modeling of ASD in mice provides a valuable tool for the identification of genes that may play a pivotal role in the disease pathology or for the development of novel drugs targeting ASD.
Researchers from the GlaxoSmithKline and The Rockefeller University collaborated on this study.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in 4 out of 10 pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.